Supplemental Table 8.  Baseline characteristic between dose levels of steroid use per day in matched total patients

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 　 | 　 | Non- steroid  | 　 | 1st Quartile | 　 | 2nd Quartile | 　 | 3rd Quartile | 　 | 4th Quartile |
| **Baseline characterisitics** |  | n=5445 |  | n=1361 |  | n=1365 |  | n=1359 |  | n=1360 |
|  |  | n(%) | 　 | n(%) | 　 | n(%) | 　 | n(%) | 　 | n(%) |
| Age (years) |  | 67.78±16.55 |  | 66.81±15.98 |  | 68.15±16.47 |  | 68.68±16.19 |  | 68.03±16.41 |
| Gender (Male) |  | 3240 (59.5%) |  | 806 (59.22%) |  | 805 (58.97%) |  | 799 (58.79%) |  | 813 (59.78%) |
| Presenting complaint |  |  |  |  |  |  |  |  |  |
|  | Cardiac event | 1067 (19.6%) |  | 305 (22.41%) |  | 260 (19.05%) |  | 250 (18.4%) |  | 255 (18.75%) |
|  | Respiratory event | 711 (13.06%) |  | 181 (13.3%) |  | 158 (11.58%) |  | 174 (12.8%) |  | 173 (12.72%) |
|  | Other event | 1175 (21.58%) |  | 357 (26.23%) |  | 310 (22.71%) |  | 259 (19.06%) |  | 250 (18.38%) |
|  | Unknown | 2492 (45.77%) |  | 518 (38.06%) |  | 637 (46.67%) |  | 676 (49.74%) |  | 682 (50.15%) |
| Diabetes mellitus |  | 1711 (31.42%) |  | 465 (34.17%) |  | 423 (30.99%) |  | 436 (32.08%) |  | 397 (29.19%) |
| Hypertension |  | 2575 (47.29%) |  | 704 (51.73%) |  | 635 (46.52%) |  | 658 (48.42%) |  | 592 (43.53%) |
| Coronary artery disease | 1050 (19.28%) |  | 319 (23.44%) |  | 263 (19.27%) |  | 232 (17.07%) |  | 216 (15.88%) |
| Heart failure |  | 743 (13.65%) |  | 222 (16.31%) |  | 175 (12.82%) |  | 164 (12.07%) |  | 179 (13.16%) |
| Atrial fibrillation |  | 281 (5.16%) |  | 60 (4.41%) |  | 84 (6.15%) |  | 70 (5.15%) |  | 73 (5.37%) |
| Chronic kidney disease | 567 (10.41%) |  | 193 (14.18%) |  | 147 (10.77%) |  | 139 (10.23%) |  | 100 (7.35%) |
| Malignancy |  | 529 (9.72%) |  | 126 (9.26%) |  | 142 (10.4%) |  | 157 (11.55%) |  | 133 (9.78%) |
| Chronic obstructive lung disease | 1032 (18.95%) |  | 200 (14.7%) |  | 251 (18.39%) |  | 256 (18.84%) |  | 317 (23.31%) |
| Asthma |  | 406 (7.46%) |  | 47 (3.45%) |  | 70 (5.13%) |  | 98 (7.21%) |  | 193 (14.19%) |
| Adrenal insufficiency |  | 35 (0.64%) |  | 2 (0.15%) |  | 8 (0.59%) |  | 15 (1.1%) |  | 13 (0.96%) |
| Autoimmune disease |  | 94 (1.73%) |  | 15 (1.1%) |  | 24 (1.76%) |  | 28 (2.06%) |  | 29 (2.13%) |
| Steroid use prior to cardiac arrest (1-year) | 2166 (39.78%) |  | 465 (34.17%) |  | 551 (40.37%) |  | 566 (41.65%) |  | 613 (45.07%) |
| Shockable rhythm |  | 1338 (24.57%) |  | 385 (28.29%) |  | 346 (25.35%) |  | 296 (21.78%) |  | 314 (23.09%) |
| Epinephrine dosage (mg) | 5.72±5.23 |  | 4.29±4.38 |  | 5.90±5.77 |  | 6.01±5.32 |  | 6.52±5.25 |
| Vasopressin  |  | 22 (0.4%) |  | 3 (0.22%) |  | 3 (0.22%) |  | 1 (0.07%) |  | 12 (0.88%) |
| Medical center |  | 1621 (29.77%) |  | 387 (28.43%) |  | 452 (33.11%) |  | 411 (30.24%) |  | 390 (28.68%) |
| Urbanization level of residence |  |  |  |  |  |  |  |  |  |
|  | 1 (high) | 1439 (26.43%) |  | 338 (24.83%) |  | 384 (28.13%) |  | 347 (25.53%) |  | 356 (26.18%) |
|  | 2 | 2270 (41.69%) |  | 614 (45.11%) |  | 559 (40.95%) |  | 550 (40.47%) |  | 578 (42.5%) |
|  | 3 | 471 (8.65%) |  | 125 (9.18%) |  | 123 (9.01%) |  | 129 (9.49%) |  | 97 (7.13%) |
|  | ≥ 4 (low) | 1265 (23.23%) |  | 284 (20.87%) |  | 299 (21.9%) |  | 333 (24.5%) |  | 329 (24.19%) |
| Geographic distribution |  |  |  |  |  |  |  |  |  |
|  | Taipei | 1993 (36.6%) |  | 485 (35.64%) |  | 500 (36.63%) |  | 476 (35.03%) |  | 532 (39.12%) |
|  | Northern | 731 (13.43%) |  | 197 (14.47%) |  | 175 (12.82%) |  | 154 (11.33%) |  | 173 (12.72%) |
|  | Central | 1482 (27.22%) |  | 386 (28.36%) |  | 423 (30.99%) |  | 406 (29.87%) |  | 308 (22.65%) |
|  | Southern | 553 (10.16%) |  | 116 (8.52%) |  | 134 (9.82%) |  | 155 (11.41%) |  | 150 (11.03%) |
|  | Kaopin | 445 (8.17%) |  | 126 (9.26%) |  | 82 (6.01%) |  | 112 (8.24%) |  | 107 (7.87%) |
| 　 | Eastern | 241 (4.43%) | 　 | 51 (3.75%) | 　 | 51 (3.74%) | 　 | 56 (4.12%) | 　 | 90 (6.62%) |